CLN Stock Overview
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł25.35 |
| 52 Week High | zł32.90 |
| 52 Week Low | zł14.62 |
| Beta | 0.78 |
| 1 Month Change | -3.98% |
| 3 Month Change | -8.48% |
| 1 Year Change | 63.55% |
| 3 Year Change | -23.18% |
| 5 Year Change | -38.10% |
| Change since IPO | 13.78% |
Recent News & Updates
Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position
Nov 28
A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price
Aug 21Recent updates
Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position
Nov 28A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price
Aug 21Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Shareholder Returns
| CLN | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 5.4% | 2.3% | -2.5% |
| 1Y | 63.5% | 28.7% | -4.5% |
Return vs Industry: CLN exceeded the Polish Pharmaceuticals industry which returned 28.7% over the past year.
Return vs Market: CLN exceeded the Polish Market which returned -4.5% over the past year.
Price Volatility
| CLN volatility | |
|---|---|
| CLN Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: CLN has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: CLN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 562 | Maciej Wieczorek | www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.
Celon Pharma S.A. Fundamentals Summary
| CLN fundamental statistics | |
|---|---|
| Market cap | zł1.37b |
| Earnings (TTM) | zł18.51m |
| Revenue (TTM) | zł209.54m |
73.8x
P/E Ratio6.5x
P/S RatioIs CLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLN income statement (TTM) | |
|---|---|
| Revenue | zł209.54m |
| Cost of Revenue | zł64.10m |
| Gross Profit | zł145.43m |
| Other Expenses | zł126.92m |
| Earnings | zł18.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 69.41% |
| Net Profit Margin | 8.83% |
| Debt/Equity Ratio | 0% |
How did CLN perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield23%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 01:35 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Celon Pharma S.A. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Vladimira Urbankova | Erste Group Bank AG |